ShouTi secures $100M to hit biologic and peptide targets with small molecules October 20, 2021 Auto Bot Artificial Intelligence, BioPharma, biopharma nl, cardiovascular disease, China, Chronic conditions, deals, investing, metabolic disorders, South San Francisco, Startups 0 ShouTi Pharmaceuticals, a startup that brings computational techniques to drug discovery, has raised $100 million in Series B financing. The clinical-stage biotech designs small molecules intended to do the work of biologic and peptide drugs.